A randomized phase I Bayesian dose escalation design for the combination of anti-cancer drugs-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A randomized phase I Bayesian dose escalation design for the combination of anti-cancer drugs

Published:2014-04-09 Issue:3 Volume:13 Page:196-207
ISSN:1539-1604
Container-title:Pharmaceutical Statistics
language:en
Short-container-title:Pharmaceut. Statist.

Author:

Dejardin David¹,Lesaffre Emmanuel¹²,Hamberg Paul³⁴,Verweij Jaap³⁴

Affiliation:

1. Interuniversity Institute for Biostatistics and Statistical Bioinformatics; KULeuven; Leuven & Universiteit Hasselt, Diepenbeek Belgium

2. Department of Biostatistics; Erasmus MC, Rotterdam The Netherlands

3. Department of Internal Medicine; Sint Franciscus Gasthuis, Rotterdam The Netherlands

4. Department of Medical Oncology; Erasmus MC - Daniel den Hoed Cancer Center; Rotterdam The Netherlands

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/pst.1618/fullpdf

Reference17 articles.

1. Clinical Trials

2. Phase I studies of drug combinations;Verweij;Journal of Clinical Oncology,2010

3. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents;Ratain;Journal of the National Cancer Institute,1993

4. Etoposide combined with interferon alfa-2b: Novel exploitation of established etoposide pharmacokinetics and pharmacodynamics;Mick;Clinical Pharmacology & Therapeutics,1996

5. Dose-escalation models for combination phase I trials in oncology;Hamberg;European Journal pf Cancer,2010-11

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation;Clinical Cancer Research;2021-09-13

2. Quickly evaluating the synergistic effects of top anti-cancer drugs by the computer high performance computing power and complex network visualization;Journal of Intelligent & Fuzzy Systems;2020-01-09

3. Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology;JNCI: Journal of the National Cancer Institute;2018-12-17

4. From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely;Clinical Cancer Research;2017-08-31

5. An Escalation for Bivariate Binary Endpoints Controlling the Risk of Overtoxicity (EBE-CRO): Managing Efficacy and Toxicity in Early Oncology Clinical Trials;Journal of Biopharmaceutical Statistics;2017-04-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3